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Abstract
Introduction: Besides routine serum markers of inflammatory diseases, the diagnostic potential of selected urinary proteins has not been fully 
exploited yet. Former studies revealed that urinary orosomucoid (u-ORM) might have complementary information in inflammatory disorders. Our 
aim was to develop and validate a fully automated method for u-ORM measurements and to evaluate its potential clinical impact on systemic in-
flammatory diseases.
Materials and methods: A particle-enhanced immune turbidimetric assay was validated for a Cobas 8000/c502 analyzer to determine u-ORM 
levels. Spot urine samples from 72 healthy individuals, 28 patients with Crohn’s disease and 30 septic patients were studied.
Results: Our assay time was 10 minutes and the detection limit of u-ORM was 0.02 mg/L. The intra- and inter-assay imprecision expressed as CV 
was less than 5%, and the recovery ranged between 95–103%. Within 10 to 60 years of age, a preliminary reference range for urinary orosomucoid/
creatinine ratio (u-ORM/u-CREAT) was found to be 0.08 (0.01–0.24) mg/mmol [median (2.5–97.5 percentiles)]. Compared to controls, a five-fold 
increase of u-ORM/u-CREAT values in Crohn’s disease and approximately a 240-fold increase in sepsis were observed.
Conclusions: We set up a fast, sensitive and precise turbidimetric approach for automated u-ORM determination. Our highly sensitive assay is ideal 
for routine u-ORM measurements and might be a potential novel laboratory test in the management of systemic inflammatory processes.
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The leading causes of global mortality – cardiovas-
cular diseases, diabetes mellitus, malignancies and 
infections – and their complications are all associ-
ated with activation of the inflammatory system. 
Laboratory parameters are fundamental in these 
disorders not only for early diagnosis, but also for 
the detection of complications. Furthermore, bio-
markers are particularly useful in risk stratification, 
prediction of disease progression and outcome. It 
is additionally advantageous, if a marker can be 
measured from a non-invasively obtained sample 
by a fast, automated routine diagnostic procedure.
Human orosomucoid (α-1-acid glycoprotein, ORM) 
is an extensively glycosylated, abundant constitu-
ent of the α-1-globulin family (1). It is an acute 
phase protein produced mainly by the liver with a 
molecular mass of 41–43 kDa; however, lower 
amounts of ORM can be also synthesized by leu-
kocytes and endothelial cells (2). As a member of 
the lipocalin protein family, ORM plays a role in 
transporting biomolecules and drugs (3). Further-
more, it has been revealed that ORM takes part in 
maintaining capillary perm-selectivity, represent-
ing its immunomodulatory effect (4,5).
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As an acute phase protein, serum concentrations 
of ORM can increase up to two-three fold in malig-
nancies, inflammatory diseases and severe infec-
tion, thus it serves as a general, non-specific in-
flammatory marker (6,7). ORM can also be found in 
the urine with much lower concentrations than in 
serum. However, information on its role in the 
urine is limited. Most probably it is filtrated 
through the glomeruli, but the mechanism of uri-
nary excretion of ORM is not well clarified (8).
Former studies revealed that ORM is a considera-
bly abundant component of urinary proteins (8-
21). Markedly increased urinary excretion of ORM 
was found after physical exercise, in acute inflam-
mation, preeclampsia, lupus and also in bladder 
cancer (9-14). In spite of the fact that the elevation 
of urinary orosomucoid (u-ORM) concentrations 
seems to be a non-specific marker, several publica-
tions stated that u-ORM might serve advanta-
geous information on early monitoring of certain 
inflammatory disorders. Elevated u-ORM was de-
scribed in diabetes mellitus associated with the 
ongoing chronic low-grade inflammation and en-
dothelial dysfunction and was considered to be an 
independent predictor of diabetic nephropathy 
and cardiovascular mortality among patients with 
type 2 diabetes (15-19). Recent findings suggest 
that it also might be a potential novel marker for 
the early detection of chronic heart failure (20). 
Previously we showed that u-ORM could be a 
more sensitive marker of inflammation than serum 
ORM which rises only 2-fold in contrast to even 
200-fold increase of u-ORM in sepsis (21). Others 
also showed that the elevation of u-ORM is much 
more considerable than that of serum ORM in rela-
tion to inflammatory diseases (10,11,17). These re-
sults indicate that u-ORM is a reliable marker of 
chronic and acute inflammatory disorders and 
provides valuable supplementary information for 
daily clinical practice.
In spite of promising literature data on the poten-
tial utility of u-ORM, a commercially available, sen-
sitive, fast and fully automated laboratory test for 
u-ORM measurement is unavailable yet. Several 
different methods exist to determine u-ORM 
(western blotting, radioimmunoassay, ELISA), 
though all of these analyses are not appropriate 
for routine work. In our previous studies we per-
formed an in-house western blot method and a la-
ser nephelometric assay for u-ORM measurements 
in several patient groups and in healthy individu-
als (21,22). Although we could determine ORM val-
ues in urine, neither techniques are usable in daily 
routine: western blotting is time consuming; 
moreover, it is not accurate enough, while neph-
elometry was not properly sensitive for values 
found in healthy individuals. Clinical application 
requires a simple, reliable, fast and sensitive auto-
mated method. For this purpose, we decided to 
adapt and validate a particle-enhanced turbidi-
metric assay on a fully automated clinical chemis-
try analyzer for the quantitative determination of 
ORM in urine. Our further aim was to determine 
preliminary reference ranges of u-ORM in different 
age groups of healthy individuals and to investi-




Instrumentation, reagents, assay conditions
The latex particle-enhanced turbidimetric (PET) 
assay for u-ORM measurement was carried out on 
the c502 module of a Cobas 8000 analyzer (Roche 
Diagnostics GmbH, Mannheim, Germany). An 
open developmental channel was used for this ap-
plication.
The determination of u-ORM was performed by 
using anti human rabbit Orosomucoid Immu-
noparticles (ref. no. OA504, Dako Denmark A/S, 
Glostrup, Denmark) and Reaction Buffer (ref. no. 
PO1812, Dako Denmark A/S, Glostrup, Denmark). 
The antigen, antibody and buffer volumes were 
optimized during the validation period.
Considering that there are no commercially availa-
ble urinary ORM calibrators and controls, dilution 
series of N Protein Standard SL for BN II Systems 
(ref. no. OQIM13, Siemens Healthcare Diagnostics 
GmbH, Marburg, Germany) with 788 mg/L oroso-
mucoid concentration were used for calibration 
and two different dilutions (4.125 and 0.825 mg/L, 
respectively) of N/T Protein Control SL/L (ref. no. 
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OQIN13, Siemens Healthcare Diagnostics GmbH, 
Marburg, Germany) were applied as controls. All 
the dilutions of calibrators, controls and samples 
were made by sterile 154 mmol/L NaCl solution 
which was also used as blank sample.
The optimal assay volumes were assessed using a 
wide concentration range of the calibrator (0.1–
31.5 mg/L), and a working range below the equiv-
alence zone was chosen (antibody excess). Two-
point end assay type was set using 10-minute re-
action time. The wavelength used for the turbidi-
metric reaction was 546 nm and delta absorbance 
was calculated after pipetting the latex-antibody 
particles (self-blank, between 38–70 measuring 
points). The calibrator/control/sample volume was 
7 µL and the latex-antibody volume was 40 µL. Full 
calibration was performed by applying a six-point 
standard curve (blank plus five different dilutions 
of the calibrator) and the spline graph evaluation 
method was used. The assay was performed at 
37 °C.
Validation protocol
The validation protocol of our u-ORM assay is 
based on the 2nd edition of Eurachem guidelines 
(23). The analytical limits were obtained by using 
the absorbance data of 30 independent determi-
nations of blank samples. Mean, standard devia-
tion (SD) and coefficients of variation (CV) were 
calculated. Limit of blank (LOB) was determined as 
the mean absorbance value + 1.645 x SD of the 
blank samples (24), limit of detection (LOD) was 
calculated as the blank mean + 3 x SD, while limit 
of quantification (LOQ) as the blank mean value + 
10 x SD. The corresponding concentrations were 
defined using cubic spline interpolation of the ab-
sorbance data by the Origin Pro8 software (Origin-
Lab Corporation, Northampton, USA). Functional 
sensitivity was evaluated from five independent 
dilution series of a urine sample (0.025 - 0.390 
mg/L) measured on five consecutive days in two 
parallels. Functional sensitivity was set at the low-
est u-ORM concentration where the CV reached 
20%.
For intra- and inter-assay imprecision measure-
ments we used dilutions of PreciControl ClinChem 
Multi 2 (PC2, ref. no. 05117216 190, Roche Diagnos-
tics GmbH, Mannheim, Germany) with 845 mg/L 
orosomucoid concentration. Four different dilu-
tion levels of PC2 were used for the assessment of 
intra-assay (within run) imprecision by ten parallel 
measurements on the same day and for that of in-
ter-assay (between run) imprecision using dupli-
cate measurements on ten consecutive days. Also, 
recovery was calculated from the measured and 
theoretical value at four levels of PC2 and was ex-
pressed as % (N = 40 for each level). Linearity was 
determined by two parallel measurements of ten 
different dilutions of a urine sample in the range of 
0.10–4.68 mg/L.
Five different urine samples (ranging from 0.52 to 
4.11 mg/L) were selected for stability studies. 
Specimens were divided into aliquots and were 
stored at 2–8 °C for 10 days. U-ORM was deter-
mined right after sample collection and on the 3rd, 
5th, 8th and 10th day, respectively. Urinary oroso-
mucoid stability after freezing - thawing cycles 
was also assessed. Aliquots of the samples without 
any preservatives were frozen at -70 °C and subse-
quently thawed at 37 °C, then u-ORM was meas-
ured thereafter, five freezing – thawing cycles 
were performed with a simultaneous u-ORM de-
termination.
Method comparison
A reference method for u-ORM measurements is 
not available; therefore, our results measured by 
turbidimetric assay were compared to results ob-
tained by western blotting which was previously 
used, too (21). Urine samples from healthy individ-
uals and various patients were analyzed by west-
ern blotting using primary anti-orosomucoid anti-
bodies (ref. no. Q0326, Dako Denmark A/S, 
Glostrup, Denmark) and secondary horseradish 
peroxidase conjugated anti-rabbit immunoglobu-
lins (ref. no. P0217, Dako Denmark A/S, Glostrup, 
Denmark). For the chemiluminescent detection 
and immunoblotting evaluation a charged cou-
pled device (CCD) camera and software (Syngene, 
Cambridge, UK) was used. Dilution series of the N 
Protein Standard SL (ref. no. OQIM13, Siemens 
Healthcare Diagnostics GmbH, Marburg, Germa-
ny) were used for calibration of the western blot 
method after densitometry by plotting the chemi-
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luminescence signal of the standards vs the stand-
ards’ concentrations. A linear regression fit was ap-
plied (R2 = 0.996). For the quantitative evaluation 
of the samples in each blot the same urine sample 
with known u-ORM concentration of a healthy in-
dividual was applied as an internal standard.
Subjects
In order to determine the reference range for u-
ORM, healthy volunteers (N = 72) were recruited be-
tween the age of 10 and 60 years among whom 
three age groups were created (10–20, 21–40, and 
41–60 years, respectively). Healthy state was as-
sessed if the person had no chronic illness, no com-
plaints, and no symptoms on medical examination 
and did not take prescribed medicines. Accordingly, 
exclusion criteria were inflammation (based on hs-
CRP, white blood cell count and clinical signs), any 
kind of chronic diseases (based on medical records) 
or the lack of consent. U-ORM was also analyzed in 
patients with clinical diagnosis of Crohn’s disease (N 
= 28) independently from disease activity and in pa-
tients with sepsis (N = 30). Our study was performed 
from January 2014 to November 2015. The study 
was approved by the Regional Ethics Committee of 
the University of Pécs, Medical School in accord-
ance with the Helsinki declaration (no. 4327.316-
2900/KK15/2011). Every patient and control individ-
ual was fully informed and written consent was ob-
tained from all of them. Spontaneous random urine 
samples and venous blood were simultaneously 
obtained from the participants. After centrifugation 
(1500 x g, 10 minutes) of clotted blood and urine 
samples, supernatants were collected into aliquots 
and stored at -70 °C until use. We measured urinary 
total protein (u-TP) and creatinine on Cobas 8000 
analyzer (Roche Diagnostics GmbH, Mannheim, 
Germany). We expressed our u-ORM data not only 
in mg/L concentrations but also in u-ORM/ urinary 
creatinine (u-CREAT) ratio (mg/mmol) and in u-
ORM/u-TP (%) proportion. Also, hs-CRP and creati-
nine were measured from serum samples.
Statistical analyses
The distribution of our variables was determined 
by Shapiro-Wilk analyses. For comparison of the 
laboratory parameters of our patient groups 
Kruskal-Wallis test was used when the distribution 
was not normal. To assess gender differences the 
Mann Whitney U test was performed. Reference 
interval for u-ORM, u-ORM/u-CREAT and u-ORM/u-
TP were determined at 95% confidence interval. 
Passing- Bablok regression analyses and Bland-Alt-
man plots were used to compare the methods. 
The continuous variables were expressed as medi-
ans with percentiles in case of non-normal distri-
bution. A p value of P < 0.05 was considered as sta-
tistically significant. Statistical analyses were per-
formed by MedCalc Statistical Software version 
16.8 (MedCalc Software, Ostend, Belgium).
Results
Validation data
The calibration curve obtained from 22 independ-
ent calibrations is shown in Figure 1A. The calibrat-
ed working range for u-ORM measurements was 
between 0.16–5.25 mg/L. Samples at above 5.25 
mg/L u-ORM concentrations had to be diluted due 
to the hook effect experienced (Figure 1B) while 
those under the lowest calibration point (0.16 
mg/L) of the assay could be determined down to 
at least of 0.08 mg/L. LOB, LOD, LOQ of our u-ORM 
assay were calculated as previously described, and 
were 0.0095, 0.02 and 0.08 mg/L, respectively. The 
functional sensitivity of our assay was assessed to 
be 0.03 mg/L (Figure 2A).
Both intra- and inter- assay imprecision was deter-
mined to be less than 5% of CV and even recovery 
of our u-ORM assay was found to vary between 
95.69 - 102.51% (Table 1). The assay showed good 
linearity (R2 = 0.999) in the range of 0.1–4.68 mg/L 
(Figure 2B).
Stability studies
During 10 days of storage at 2–8 °C we found no 
significant difference in the recovery of u-ORM 
concentrations of the urine samples (97.2–109.2%). 
Furthermore, we found no significant decrease in 
u-ORM concentrations after repeated freeze-thaw 
cycles. Even at the 5th cycle the recovery remained 
quite acceptable as presented in Table 2.
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Intra-assay (N = 10) Inter-assay (N = 20)
Mean ± SD, 
mg/L CV, % Recovery, % Mean ± SD, mg/L CV, % Recovery, %
c1* 3.86 3.73 ± 0.08 2.01 96.70 3.83 ± 0.13 3.50 99.24
c2* 2.11 2.06 ± 0.01 0.45 97.98 2.17 ± 0.04 1.77 102.51
c3* 0.64 0.62 ± 0.01 1.92 95.69 0.63 ± 0.03 4.29 98.31
c4* 0.30 0.30 ± 0.01 4.44 100.71 0.30 ± 0.01 4.55 100.18
*Samples were dilutions from PC2 control. SD – standard deviation. CV – coefficient of variation.
Table 1. Imprecision and recovery data of u-ORM assay.
Figure 1. Calibration and dose response curve of u-ORM.
(A) Cumulative graph of a 6-point calibration curve of the assay in the range of 0.16–5.25 mg/L with spline graph fitting. Calibrators’ 
mean ± standard deviations from 22 separate calibrations are represented by red dots and bars.
(B) Dose response curve from serial dilutions of the calibrators in the range of 0.1-31.5 mg/L.
Figure 2. Functional sensitivity and linearity of the u-ORM assay.
(A) Functional sensitivity was determined to be 0.03 mg/L (dashed line).
(B) Linearity was studied by diluting a urine sample within the range of 4.68–0.10 mg/L in 10 different dilutions. The regression line 
equation (y = bx + a) is: y = 1.021 x + 0.015, R² = 0.999. a - Regression line’s intercept. b - Regression line’s slope. R2 –Coefficient of de-













0 1 2 3 4 5 6













































































Biochemia Medica 2016;26(3):421–30  http://dx.doi.org/10.11613/BM.2016.044 
426
Kustán P. et al. Urinary orosomucoid as inflammatory marker
Method comparison
96 samples with a u-ORM concentration range of 
0.23–292 mg/L were analyzed by western blotting 
and the new turbidimetric assay. We found a 
strong positive correlation (r = 0.924, p < 0.001) be-
tween the results obtained by the two methods; 
however, the concentrations determined by west-
ern blotting were lower than those obtained by 
immune turbidimetry and a proportional differ-
ence between the methods was found. The com-
parison of the methods is illustrated in Figure 3.
Reference range, patients
The data of healthy individuals are listed in Table 3. 
We found no significant differences in u-ORM ex-
cretion between the three age-groups of healthy 
volunteers, therefore we suggest pooling all the 
data and using a common reference value for all 
cases between 10–60 years. Based on the sponta-
neous u-ORM concentrations of 72 healthy per-
sons, the following reference intervals, expressed 
as median (2.5–97.5 percentiles), could be defined: 
0.69 (0.13–2.96) mg/L for u-ORM, 0.08 (0.01–0.24) 
Initial u-ORM 
concentration, mg/L
Storage at 2-8 °C Thawing-freezing cycles
Day 3, % Day 5, % Day 8, % Day 10, % Cycle 1, % Cycle 2, % Cycle 3, % Cycle 4, % Cycle 5, %
4.11 98.4 103.6 105.7 109.2 106.3 108.3 109.5 111.7 112.9
3.61 99.1 101.5 102.4 106.6 105.5 106.7 106.4 105.3 104.6
2.74 98.9 100.5 103.0 105.8 104.6 105.7 104.2 104.5 103.6
1.23 97.2 98.8 99.1 107.9 106.3 108.2 109.4 112.6 113.1
0.52 104.5 98.8 -* -* 104.5 104.8 102.0 107.6 110.0
Urinary ORM concentrations are referred to initial concentration and expressed in %. *sample with 0.52 mg/L initial concentration 
could not be tested on day 8 and 10 because of non-expected sample error.
Table 2. Stability studies of urinary orosomucoid
Figure 3. Comparison of quantitative western blotting and the new automated turbidimetric assay for u-ORM measurement.
(A) Passing-Bablok regression analysis. Regression line equation (y = a (95% CI) + b (95% CI) x) is y = 0.154 (-0.396 to 0.574) + 2.143 
(1.882 to 2.523) x. a - Regression line’s intercept. b - Regression line’s slope. 95% CI - 95% confidence interval. Cusum test for linearity 
showed no significant deviation from linearity (P = 0.95). Solid line - regression line. Dashed lines - 95% CI for the regression line. Dot-
ted line - identity line (x = y).
(B) Bland-Altman plot of the mean concentration against the difference for the compared methods. Solid line (mean) – mean differ-
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mg/mmol for u-ORM/u-CREAT and 1.00 (0.21–
3.58)% for u-ORM/u-TP proportion. There was no 
significant difference in u-ORM/u-CREAT between 
females and males in the three control groups. 
However, significantly elevated u-ORM concentra-
tion (P = 0.034) and u-ORM/u-TP (P = 0.023) were 
observed in males compared to females (1.3 mg/L 
and 2.29%, 0.49 mg/L and 0.62%, respectively) in 
the age group of 41–60 years. Regarding past 
medical history and laboratory data (serum creati-
nine concentrations) in our control group, normal 
kidney function was hypothesized and also no 
proteinuria and no inflammatory activity were ob-
served in healthy individuals.
We found significantly elevated (P < 0.001) u-ORM 
concentrations in inflammatory diseases (Table 4). 
Compared to controls, about a 5-fold increase of 
u-ORM/u-CREAT ratios in Crohn’s disease (0.40 
mg/mmol, P < 0.001) and an extreme, approxi-
mately 240-fold elevation in sepsis (19.13 mg/
mmol, P < 0.001) was found. The observed u-ORM 
concentration in severe sepsis was significantly 
higher (P < 0.001) than that in morbus Crohn. Like-
wise, significant elevation was discovered in u-
ORM/u-TP proportions both in sepsis and in 
Crohn’s disease compared to healthy people (P < 
0.001).
Discussion
In the present study we reported the adaptation 






N = 23 P
Total control group, 
N = 72
Females, N (proportion) 13 (0.43) 9 (0.47) 15 (0.65) NA 37 (0.51)
Age, years 14 (10–18) 29 (21–39) 51 (40–58) NA 23 (10–58)
U-ORM, mg/L 0.56 (0.10–2.96) 0.71 (0.25–2.30) 0.76 (0.14–2.64) 0.730 0.69 (0.13–2.96)
U-ORM / u-CREAT, mg/mmol 0.09 (0.02–0.19) 0.07 (0.01–0.35) 0.08 (0.02–0.24) 0.590 0.08 (0.01–0.24)
U-ORM / u-TP, % 0.91 (0.21–2.34) 1.09 (0.24–3.24) 1.36 (0.32–4.32) 0.170 1.00 (0.21–3.58)
Data are presented as median and 2.5–97.5 percentiles. Age is presented as median (range). Kruskal-Wallis test was used to 
compare the different age groups of controls. P < 0.05 was considered statistically significant. NA–not applicable. U-ORM – urinary 
orosomucoid. u-CREAT – urinary creatinine. u-TP – urinary total protein.
Table 3. Preliminary reference ranges of u-ORM values in healthy individuals





N = 30 P
Females, N (proportion) 37 (0.51) 15 (0.54) 11 (0.37) NA
Age, years 23 (10–58) 27 (12–62) 67 (30–82) NA
Serum creatinine, (µmol/L) 64 (55–75) 59 (50–71) 130 (104–181) < 0.001
hs-CRP, mg/L 0.60 (0.30–1.50) 6.10 (2.95–14.16) 260.09 (158.16–335.73) < 0.001
U-ORM, mg/L 0.69 (0.33–1.13) 4.15 (1.97–10.30) 90.21 (42.01–137.23) < 0.001
U-ORM / u-CREAT, mg/mmol 0.08 (0.05–0.15) 0.40 (0.20–1.08) 19.13 (13.04–32.80) < 0.001
U-ORM/u-TP, % 1.00 (0.54–1.69) 3.72 (2.48–6.41) 18.71 (11.88–34.86) < 0.001
Data are presented as median and 25–75 percentiles. Age is presented as median (range). Kruskal-Wallis test was used to compare 
variables in different groups. P < 0.05 was considered statistically significant. NA – not applicable. Hs-CRP – high sensitive 
C-reactive protein. U-ORM – urinary orosomucoid. u-CREAT – urinary creatinine. u-TP – urinary total protein.
Table 4. Urinary orosomucoid concentrations in inflammatory diseases
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metric assay for u-ORM measurements on Cobas 
8000/c502 platform, and also pointed out its po-
tential clinical relevance.
This new turbidimetric approach was set up to be 
fast, sensitive and precise, therefore it is ideal for 
routine u-ORM determinations. The imprecision of 
our method was tested by using diluted controls 
with a CV at around 5%. Therefore, taken real urine 
samples we accepted the quality requirements for 
this assay with an imprecision of less than 10% as 
CV. The test requires only 10 minutes. Due to the 
extraordinarily low LOQ (0.08 mg/L) and the good 
functional sensitivity (0.03 mg/L) our PET assay en-
ables the quantitative u-ORM determination in all 
healthy individuals and, after proper dilution in 
patients suffering from systemic inflammatory dis-
eases. However, due to the narrow security zone, a 
20-fold predilution of all urine samples is suggest-
ed in order to automatically extend the measura-
ble concentration limit up to 105 mg/L. Samples 
containing low orosomucoid concentrations (< 1 
mg/L) can be retested without dilution however 
these samples’ data has no clinical relevance.
Although, u-ORM seems to be a promising marker 
in diseases with systemic inflammatory activation, 
up to now only Christiansen et al. described an au-
tomated turbidimetric immunoassay for u-ORM 
determination similar to ours (25). Nevertheless, 
our assay settings allow more sensitive determina-
tion compared to their detection limit (0.05 mg/L); 
moreover our method seems to be more precise 
in the lower concentration range.
In agreement with other studies we also proved 
that ORM in urine is stable in vitro (25, 26). Our re-
sults showed that within 10 days the u-ORM con-
centrations are considerably constant in samples 
without additives and stored at 2-8 °C. Further-
more, we found no loss in u-ORM concentration 
during 5 freezing-thawing cycles. These results 
support that urine samples can be stored at 2-8 °C 
even for 10 days before analysis, and in case of de-
layed analysis for any reason, samples can be fro-
zen and tested later.
In our preliminary studies, we found dramatically 
higher u-ORM concentrations in sepsis by immu-
noblotting (21,22). Good correlation between the 
immunoblotting results and this PET immunoas-
say was found, although the methods are not di-
rectly comparable due to systemic bias. The use of 
quantitative u-ORM determination by immunob-
lotting, on the grounds of the methodological un-
certainty, imprecision and time demand means 
that western blotting is unsuitable for daily rou-
tine u-ORM testing.
In our present work, we found a low urinary oroso-
mucoid excretion rate in healthy persons. The ex-
pression of urinary protein concentrations referred 
to urinary creatinine is necessary in order to re-
duce the large inter-individual variability in the 
amount of excreted protein of urine samples. 
Based on spot urine samples of 72 healthy volun-
teers from different age groups between 10–60 
years, we determined a preliminary reference 
range for u-ORM/u-CREAT to be 0.01–0.24 mg/
mmol with a median of 0.08 mg/mmol. Our results 
are in accordance with former studies (25, 27, 28). 
Tencer et al. analyzed 95 healthy adults and estab-
lished an upper reference limit for u-ORM/u-CREAT 
at 0.7 mg/mmol. They found no correlation with 
age and found no differences between the gender 
and the type of urine collection (27). Hjorth et al. 
determined a cut off value for u-ORM/u-CREAT by 
single radial immunodiffusion of 0.5 mg/mmol in 
233 children and in infants at the age from 1 
month to 15 years. They found significantly higher 
u-ORM concentrations in neonates in the first 
month (28). Christiansen et al. described a similar 
reference range to ours for u-ORM/u-CREAT of 
0.009–0.17 mg/mmol, with a median value of 0.04 
mg/mmol measured by their u-ORM PET assay. In 
the examined 69 adults with mean age of 43 years 
they also found higher urinary orosomucoid ex-
cretion in men than in women however, the differ-
ences disappeared when results were corrected to 
body surface area (25). We also noticed significant 
differences in u-ORM concentration between fe-
males and males above 40 but if u-ORM were cor-
rected to u-CREAT, as expectable no differences 
were observed. Therefore, u-ORM level is suggest-
ed to be expressed as urinary orosomucoid/creati-
nine ratio in order to make results easier to inter-
pret in different patients. We conclude that our 
preliminary u-ORM reference values seem to be 
http://dx.doi.org/10.11613/BM.2016.044 Biochemia Medica 2016;26(3):421–30 
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suitable for both children and adults, furthermore 
our method is precise and sensitive enough to 
measure urinary orosomucoid in every healthy in-
dividual.
To date no studies have been reported regarding 
the u-ORM concentrations in Crohn’s disease, 
however serum ORM is a well-known marker of 
morbus Crohn (29). Our observations suggest that 
elevated u-ORM may also provide additional infor-
mation on this disease. So far, in sepsis only one 
paper with 7 septic patients reported a 280-fold 
increase of u-ORM excretion, which is similar to 
our results based on a larger sample size (10). The 
observed early and extreme elevation of u-ORM 
indicates that it could be a potential biomarker of 
sepsis.
During urinalysis we further observed a relative in-
crease in u-ORM/u-TP proportion – both in Crohn’s 
disease and in sepsis, which indicates that ORM 
becomes a prominent protein component in urine 
during inflammation. The observed increase of u-
ORM values in our patient groups supports the hy-
pothesis that u-ORM elevation is caused by inflam-
matory activity. Although the cause of such eleva-
tion is probably multifactorial, both systemic in-
flammation and renal factors are supposed to be 
responsible for it. Based on our results, we further 
support the hypothesis that u-ORM is a sensitive 
marker of systemic inflammation.
This study has several limitations. Although, we 
demonstrated examples for the possible clinical 
utilization of u-ORM measurements, this study re-
ports only the analytical validation of u-ORM as-
say, and it is not a diagnostic accuracy study (30). 
Further research is required to describe the diag-
nostic performance of u-ORM in inflammatory dis-
eases. Calibrators, control materials and a refer-
ence method are not commercially available for u-
ORM measurements, only for serum testing. 
Therefore, in our u-ORM assay validation diluted 
serum calibrators/controls were used. For these 
reasons, the accuracy of our test could not be de-
termined; rather recovery was calculated from the 
appropriate dilutions of PC2. The functional sensi-
tivity was tested down to 0.025 mg/L ORM, where 
the sample’s CV exceeded 20%. The reported pre-
liminary reference range was established by inves-
tigation of a relatively small healthy population. 
The robustness of our assay could not be estimat-
ed on other automated analyzers. Furthermore, 
we may refer only to potential interferences of the 
assay, which were tested previously, and no inter-
ference was found with albumin (20 g/L), hemo-
globin (5 g/L), bilirubin (600 mg/L), creatinine (5 
g/L) and glucose (100 g/L) (25).
In conclusion, we described the validation of a 
sensitive, precise and fully automated particle-en-
hanced immune turbidimetric assay for urinary 
orosomucoid which serves early and valuable in-
formation on inflammatory diseases. Our assay is 
ideal for routine clinical utilization to measure u-
ORM as a possible novel marker of inflammatory 
activity.
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